Catalyst Calendar
Scope

Mon, Jun 1, 2026

1 updates
APRE
8:00 AM

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types Manageable tolerability confirmed across cohorts Patient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer underway;

Presentation / Abstract • Phase 1ASCO poster presentation Sat, May 30, 2026aprea.com

Wed, May 13, 2026

1 updates
APRE
6:30 AM

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051 Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose escalation ACESOT-1051 trial of WEE1 inhibitor APR-1051 Additional clinical data

Presentation / Abstract • Phase 1ASCO poster presentation Sat, May 30, 2026, 1:30 PM CTaprea.com

Tue, Apr 21, 2026

1 updates